Amarin Corporation

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Amarin Corporation
Public
Traded as NASDAQAMRN
Industry Biotechnology
Founded 1993
Headquarters Bedminster, New Jersey U.S.
Products Vascepa (AMR-101)
Number of employees
50+
Website www.amarincorp.com
www.vascepa.com

Amarin Corporation is a biopharmaceutical company founded in 1993 and headquartered in Bedminster, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa (AMR-101), a prescription grade omega-3 fatty acid.

In July 2012, their lead-candidate drug named Vascepa (AMR-101) received FDA-approval.[1][2] competing against GlaxoSmithKline's Lovaza.[3]

History[edit]

Amarin Corporation was founded in 1993[citation needed] or 1999.[4] In 2002, the company suffered losses worth $37 million, 2003 losses exceeded $19 million.[4] As of 2005 it was developing neurology drugs. It developed Miraxion to treat serious hereditary neurodegenerative disease.[4]

In December 2007, Amarin acquired Ester Neurosciences Limited for 8.1 million USD.[5] In 2011 CEO Joe Zakrzewski said that the company would like to first work on building its infrastructure out to commercialize the drug in the United States.[6]

Products and development[edit]

Vascepa[edit]

Amarin's only product is Vascepa, an Omega-3 fatty acid drug (Ethyl eicosapentaenoic acid) used to treat hypertriglyceridemia that received FDA approval in July 2012.[1][2] competing against GlaxoSmithKline's Lovaza.[7] Unlike Lovaza Vascepa was approved for patients with triglycerides of 200 mg/dL to less than 500 mg/dL.[8][9]

On 10/16/2013 after FDA's ADCOM panel had voted 9-2 against recommending to expand Vascepa's label for treatment of cardiovascular disease, shares dropped over 60%.[citation needed] As of 02/01/2015 their stock price had not recovered.[citation needed]

In March 2016, after losing a court case, the FDA agreed to allow some off-label marketing.[10]

See also[edit]

References[edit]

  1. ^ a b "Amarin Announces FDA Approval of Vascepa(TM) (icosapent ethyl) Capsules for the Reduction of Triglyceride Levels in Adult Patients With Severe Hypertriglyceridemia". Retrieved 26 July 2012.
  2. ^ a b "Amarin Prescription Fish-Oil Pill Approved - TheStreet". Retrieved 26 July 2012.
  3. ^ "FDA approves Amarin's heart pill". Reuters. 26 July 2012. Retrieved 27 July 2012.
  4. ^ a b c "Simon Kukes Prefers Drugs to Oil". Kommersant. 25 January 2005. Archived from the original on 2016-09-30. Retrieved 1 October 2016.
  5. ^ "Amarin Signs Agreement to Acquire Ester Neurosciences - Health News - redOrbit". RedOrbit. 5 December 2007. Retrieved 27 July 2012.
  6. ^ "Amarin: Mover of the Day". CNBC. April 18, 2011. Retrieved 26 July 2012.
  7. ^ "FDA approves Amarin's heart pill". Reuters. 26 July 2012. Retrieved 27 July 2012.
  8. ^ "The Rise Of Amarin's Fish Oil Should Have GSK Worried". Seeking Alpha. Retrieved 21 March 2012.
  9. ^ "Amarin's AMR101 Phase 3 ANCHOR Trial Meets all Primary and Secondary Endpoints with Statistically Significant Reductions in Triglycerides at Both 4 Gram and 2 Gram Doses and Statistically Significant Decrease in LDL-C (NASDAQ:AMRN)". Amarin. 18 April 2011. Retrieved 26 July 2012.
  10. ^ FDA Concedes Defeat on Off-Label Drug Marketing; Amarin can market its fish-oil product (Vascepa) for unapproved indications. March 2016

External links[edit]